HTBX - Heat Biologics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.91
-0.06 (-2.55%)
At close: 4:00PM EDT

1.89 -0.02 (-1.05%)
After hours: 4:44PM EDT

Stock chart is not supported by your current browser
Previous Close1.96
Open1.97
Bid1.81 x 1300
Ask2.09 x 800
Day's Range1.83 - 1.97
52 Week Range1.09 - 7.90
Volume204,604
Avg. Volume270,057
Market Cap44.173M
Beta0.58
PE Ratio (TTM)N/A
EPS (TTM)-1.80
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.33
Trade prices are not sourced from all markets
  • Zacks Small Cap Research27 days ago

    HTBX: Multiple Milestones on the Horizon

    By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Second Quarter 2018 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported second quarter 2018 results in an August 14th release and ...

  • ACCESSWIRE27 days ago

    Heat Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City

    DURHAM, NC / ACCESSWIRE / August 29, 2018 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced ...

  • InvestorPlacelast month

    Heat Biologics Stock Is a Worthwhile, Speculative Bet

    Investors still waiting for Heat Biologics (NASDAQ:HTBX) to trade at a market cap of $100 million will have to wait longer. The biotechnology company, whose market capitalization is just $43 million, which puts it in the nano-cap territory, does not have much to offer except for hope. On May 3, HTBX stock slumped by around 50% when the company filed a preliminary prospectus for the public sale of nearly 4.3 million shares.

  • ACCESSWIRElast month

    Heat Biologics Reports Second Quarter 2018 Results and Provides Corporate Update

    Completed a capital raise of $20.7 million in the second quarter of 2018 On track to report key clinical milestones beginning in Q4 2018 DURHAM, NC / ACCESSWIRE / August 14, 2018 / Heat Biologics, Inc. ...

  • ACCESSWIRE2 months ago

    Stock Performance Review on Amicus Therapeutics and Three Other Biotech Stocks

    Stock Research Monitor: HEB, HTBX, and PBYI LONDON, UK / ACCESSWIRE / July 30, 2018/ If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration . On Friday, benchmark US ...

  • Zacks Small Cap Research2 months ago

    HTBX: Heat Biologics: Making an ImPACT on Cancer

    The clinical-stage company is focused on activating T-cells with its off-the shelf ImPACT technology which activates CD8+ T-cells to induce immune responses. Its proprietary approach transforms live, allogenic cancer cells into osmotic pumps that secrete gp96 and tumor-associated peptides. The gp96 ferries the peptides to antigen presenting cells which activate the immune system.

  • ACCESSWIRE3 months ago

    Anthera Pharma and Three Additional Stocks Under Scanner in the Biotech Space

    LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on ANTH sign up now at www.wallstequities.com/registration. The nature of the operations of firms in the Biotech industry makes equities in this space more suited to aggressive, risk-tolerant investors.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Stocks to Watch: Axovant Sciences and Heat Biologics

    NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Axovant Sciences was one of the biggest gainers in the stock market on Wednesday after announcing that it has licensed an investigational gene therapy for Parkinson's Disease from Oxford BioMedica. Shares of Heat Biologics also climbed a lot higher despite any news. The company's CEO was said to present at the 2018 BIO International Convention on Wednesday.

  • Is Heat Biologics Inc (NASDAQ:HTBX) Excessively Paying Its CEO?
    Simply Wall St.4 months ago

    Is Heat Biologics Inc (NASDAQ:HTBX) Excessively Paying Its CEO?

    Jeff Wolf took the helm as Heat Biologics Inc’s (NASDAQ:HTBX) CEO and grew market cap to US$48.28M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...

  • ACCESSWIRE4 months ago

    Heat Biologics to Present at the 2018 BIO International Convention

    DURHAM, NC / ACCESSWIRE / May 30, 2018 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced ...

  • ACCESSWIRE4 months ago

    Wired News - Clementia Announced Encouraging Phase-2 Part B Data Evaluating Palovarotene for FOP Treatment

    LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want access to our free research report on Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) (''Clementia''), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CMTA as the Company's latest news hit the wire. On May 23, 2018, the Company announced positive preliminary data from Part B of its ongoing Phase-2 clinical trial evaluating palovarotene for the treatment of patients with fibrodysplasia ossificans progressive (FOP). Active-Investors.com is currently working on the research report for Heat Biologics, Inc. (NASDAQ: HTBX), which also belongs to the Healthcare sector as the Company Clementia Pharma.

  • ACCESSWIRE4 months ago

    Complimentary Technical Snapshots on Heat Biologics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want a free Stock Review on HTBX sign up now at www.wallstequities.com/registration. Today, WallStEquities.com has selected the following stocks for review: Heat Biologics Inc. (NASDAQ: HTBX), Hemispherx Biopharma Inc. (NYSE AMER: HEB), iBio Inc. (NYSE: IBIO), and Idera Pharmaceuticals Inc. (NASDAQ: IDRA).

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Heat Biologics, Inc. and Inovio Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / May 16, 2018 / Shares of biotech stocks Heat Biologics and Inovio Pharmaceuticals both saw gains in Tuesday's trading session. It was a positive data update on Inovio's HIV ...

  • ACCESSWIRE4 months ago

    Heat Biologics Reports First Quarter 2018 Results and Provides Corporate Update

    DURHAM, NC / ACCESSWIRE / May 15, 2018 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today reported ...

  • Heat Biologics Inc (NASDAQ:HTBX): Risks You Need To Consider Before Buying
    Simply Wall St.5 months ago

    Heat Biologics Inc (NASDAQ:HTBX): Risks You Need To Consider Before Buying

    If you are a shareholder in Heat Biologics Inc’s (NASDAQ:HTBX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • This Durham company is $20M richer
    American City Business Journals5 months ago

    This Durham company is $20M richer

    Durham’s Heat Biologics has banked $20.7 million in a public offering of common stock and warrants.

  • ACCESSWIRE5 months ago

    Heat Biologics, Inc. Announces Closing of $20.7 Million Public Offering

    DURHAM, NC / ACCESSWIRE / May 7, 2018 / Heat Biologics, Inc. ("Heat") (HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced the closing of its previously announced underwritten public offering of: (i) 3,000,000 shares of its Common Stock at a price of $1.44 per share together with a number of Common Warrants to purchase 1,500,000 shares of its Common Stock, and (ii) 9,500,000 Pre-funded Warrants, with each Pre-funded Warrant exercisable for one share of Common Stock, together with a number of Common Warrants to purchase 4,750,000 shares of its Common Stock. The Common Warrants will have an exercise price of $1.584, will be exercisable upon issuance and will expire five years from the date of issuance.

  • ACCESSWIRE5 months ago

    Heat Biologics, Inc. Prices $18,000,000 Public Offering

    DURHAM, NC / ACCESSWIRE / May 3, 2018 / Heat Biologics, Inc. ("Heat") (HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced the pricing of an underwritten public offering with gross proceeds of approximately $18,000,000, before deducting underwriting discounts, commissions and other offering expenses. The offering consists of: (i) 3,000,000 shares of our Common Stock together with a number of Common Warrants to purchase 1,500,000 shares of our Common Stock, and (ii) 9,500,000 Pre-funded Warrants, with each Pre-funded Warrant exercisable for one share of Common Stock, together with a number of Common Warrants to purchase 4,750,000 shares of our Common Stock.

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Heat Biologics Inc (NASDAQ: HTBX ) stock was trading ...

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: Heat Biologics and Immunomedics

    NEW YORK, NY / ACCESSWIRE / May 1, 2018 / Both Heat Biologics and Immunomedics soared higher on Monday despite neither company having any news or catalyst to explain the jumps. Both stocks also saw tremendous ...

  • Heat Bio looks to milestones, $15.5M from offering
    American City Business Journals5 months ago

    Heat Bio looks to milestones, $15.5M from offering

    Durham’s Heat Biologics (Nasdaq: HTBX) is eyeing a number of important milestones this year and looking to bank about $15.5 million in an offering of common stock and warrants.

  • ACCESSWIRE5 months ago

    Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110

    - Plans Interim Lung Cancer Phase 2 Readout in Q4 2018 and Final Readout in Q2 2019 - Expects to File IND and Enroll First Patient in ComPACT Trial in Q4 2018 - Anticipates Receipt of $6.9 Million in CPRIT ...

  • Who Are Heat Biologics Inc’s (NASDAQ:HTBX) Major Shareholders?
    Simply Wall St.5 months ago

    Who Are Heat Biologics Inc’s (NASDAQ:HTBX) Major Shareholders?

    In this analysis, my focus will be on developing a perspective on Heat Biologics Inc’s (NASDAQ:HTBX) latest ownership structure, a less discussed, but important factor. Ownership structure has been foundRead More...

  • ACCESSWIRE6 months ago

    Heat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation Platform

    100% of non-muscle invasive bladder cancer patients who generated an immune response to low dose HS-410 and also received standard of care BCG remain disease-free after 2 years DURHAM, NC / ACCESSWIRE ...

  • On heels of adopting 'poison pill', Heat Bio recruits new scientific expertise
    American City Business Journals6 months ago

    On heels of adopting 'poison pill', Heat Bio recruits new scientific expertise

    On the heels of disclosing last week that the company had adopted a stockholder rights plan – otherwise known as a "poison pill" for protection against hostile takeovers – Durham’s Heat Biologics and its subsidiary Pelican Therapeutics have recruited some new scientific expertise.